Clinical Trial Update: A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer [Phase 2]

View source ↗

Summary

This Phase 2 parallel-group trial evaluated two dosing regimens of degarelix in patients with prostate cancer, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2009-03-20